A Study of ZG005 in Patients With Advanced Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
About this trial
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Eligibility criteria
Qualifiers
Fully understand the study and voluntarily sign the informed consent form.
Male or female 18-70 years of age;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
Life expectancy ≥ 3 months;
Disqualifiers
Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
Any other malignancy within 5 years.
Trial design
Treatments tested in this trial
- ZG005 Powder for Injection
- ZG005 Powder for Injection
Treatment groups
484 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov